Download Image
    
Share
  
Post
Brequinar for COVID-19
1 study with 115 patients
Hospital Icon Control
Hospital Icon Brequinar Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Brequinar studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -205% Hospitalization -205% RCTs -205% Early -205% Favorsbrequinar Favorscontrol
Brequinar is an orally available, small molecule, host-acting antiviral that inhibits the host enzyme dihydroorotate dehydrogenase (DHODH) to block de novo pyrimidine biosynthesis, potentially inhibiting SARS-CoV-2 replication.
Apr 28
2021
 Powers et al., NCT04575038 The CRISIS2 Study: A Phase 2, Randomized, Double Blind, Placebo-controlled, Multi-center Study Assessing the Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Out-patient Adults With SARS-CoV-2
205% higher hospitalization (p=0.49) and 34% worse viral clearance. RCT 115 outpatients in the USA, showing no significant differences with brequinar treatment.